Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 27, 2016, Pages E3892-E3900

  Brauna, Christian J ^a   Brunoa, Peter M ^a   Horlbeckc, Max A ^b   Gilbertc, Luke A ^b   Weissmanc, Jonathan S ^b   Hemanna, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer genetics; Cancer models; Cancer therapeutic resistance; CRISPR; Gene regulation

Indexed keywords

CATALYTICALLY DEAD CRISPR ASSOCIATED PROTEIN 9; CISPLATIN; CRISPR ASSOCIATED PROTEIN; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CASPASE 9; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BINDING SITE; CANCER GENETICS; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCATION; GENE REPRESSION; GENE TARGETING; GENOME; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA RELAPSE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; DNA DAMAGE; DRUG RESISTANCE; EVALUATION STUDY; EXPERIMENTAL LEUKEMIA; GENE EXPRESSION REGULATION; GENETIC PROCEDURES; METABOLISM; SEQUENCE ANALYSIS;

ANIMALS; CASPASE 9; DACARBAZINE; DNA DAMAGE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC TECHNIQUES; LEUKEMIA, EXPERIMENTAL; MICE; SEQUENCE ANALYSIS, RNA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84977557474     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1600582113     Document Type: Article

References (59)

1. Pettersson E, Lundeberg J, Ahmadian A (2009) Generations of sequencing technologies. Genomics 93(2):105-111.
2. Alexandrov LB, et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415-421.
3. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214-218.
4. Roberts SA, Gordenin DA (2014) Hypermutation in human cancer genomes: Footprints and mechanisms. Nat Rev Cancer 14(12):786-800.
5. Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188(4):773-782.
6. Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93(3):1156-1160.
7. Boch J (2011) TALEs of genome targeting. Nat Biotechnol 29(2):135-136.
8. Gaj T, Gersbach CA, Barbas CF, 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397-405.
9. Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347-355.
10. Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096-1258096.
11. Shalem O, et al. (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343(6166):84-87.
12. Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343(6166):80-84.
13. Koike-Yusa H, Li Y, Tan E-P, Velasco-Herrera MdelC, Yusa K (2014) Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32(3):267-273.
14. Zhou Y, et al. (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509(7501):487-491.
15. Chen S, et al. (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160(6):1246-1260.
16. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043.
17. Bean J, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932-20937.
18. Turke AB, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77-88.
19. Yano S, et al. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22):9479-9487.
20. Curt GA, et al. (1983) Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 308(4):199-202.
21. Camgoz A, Gencer EB, Ural AU, Baran Y (2013) Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leuk Lymphoma 54(6):1279-1287.
22. Sun C, et al. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508(7494):118-122.
23. Temple G, et al.; MGC Project Team (2009) The completion of the Mammalian Gene Collection (MGC). Genome Res 19(12):2324-2333.
24. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159(3):635-646.
25. Gilbert LA, et al. (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154(2):442-451.
26. Gilbert LA, et al. (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159(3):647-661 .
27. Mali P, et al. (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31(9):833-838.
28. Perez-Pinera P, et al. (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10(10):973-976.
29. Cheng AW, et al. (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23(10):1163-1171.
30. Maeder ML, et al. (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10(10):977-979.
31. Konermann S, et al. (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536):583-588.
32. Qi LS, et al. (2013) Repurposing CRISPR as an RNA-guided platform for sequencespecific control of gene expression. Cell 152(5):1173-1183.
33. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13(20):2670-2677.
34. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137(3):413-431.
35. Brady CA, Attardi LD (2010) p53 at a glance. J Cell Sci 123(Pt 15):2527-2532.
36. Bieging KT, Mello SS, Attardi LD (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14(5):359-370.
37. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342-348.
38. Lutzker SG, Mathew R, Taller DR (2001) A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 20(23):2982-2986.
39. Fellmann C, et al. (2011) Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell 41(6):733-746.
40. Wang D, et al. (2015) Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 26(7):432-442.
41. Seipel K, Georgiev O, Schaffner W (1992) Different activation domains stimulate transcription from remote ('enhancer') and proximal ('promoter') positions. EMBO J 11(13):4961-4968.
42. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223.
43. Hegi ME, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003.
44. Medeiros BC, et al. (2012) Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol 87(1):45-50.
45. Brandwein JM, et al. (2014) Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients prescreened for low O(6)-methylguanine DNA methyltransferase expression. Br J Haematol 167(5):664-670.
46. Wu X, et al. (2014) Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32(7):670-676.
47. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32(7):677-683.
48. Jackson EL, et al. (2005) The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-10288.
49. Xie K, Doles J, Hemann MT, Walker GC (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci USA 107(48):20792-20797.
50. Doles J, et al. (2010) Suppression of Rev3, the catalytic subunit of Polzeta, sensitizes drugresistant lung tumors to chemotherapy. Proc Natl Acad Sci USA 107(48):20786-20791.
51. Yang X, et al. (2011) A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8(8):659-661.
52. Reinhardt HC, Yaffe MB (2009) Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21(2):245-255 .
53. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25(43):5912-5919.
54. Zoppoli G, et al. (2012) CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 31(4):403-418.
55. Bartkova J, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864-870.
56. Platt RJ, et al. (2014) CRISPR-Cas9 knockin mice for g enome editing and cancer modeling. Cell 159(2):440-455.
57. Beronja S, et al. (2013) RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 501(7466):185-190.
58. Williams RT, Roussel MF, Sherr CJ (2006) Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103(17):6688-6693.
59. Dickins RA, et al. (2005) Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37(11):1289-1295.